Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 13 - Medical Management of Male Infertility

  • from Section 3 - Clinical Evaluation and Treatment of Male Infertility
  • Edited by Douglas T. Carrell, Utah Center for Reproductive Medicine, Alexander W. Pastuszak, University of Utah, James M. Hotaling, Utah Center for Reproductive Medicine
  • Book:
    Men's Reproductive and Sexual Health Throughout the Lifespan
    Published online:
    06 December 2023
    Print publication:
    16 November 2023, pp 106-112

  • Summary

    Male factors significantly contribute to the issues faced by couples who are experiencing difficulties with conception. Management of the infertile male is complicated and based on a multitude of factors. Each couple is unique and has diverse issues, necessitating unique interventional approaches. Management can range from the optimization of lifestyle factors to treatment with surgery and medications. Several options exist in the medical optimization of the infertile, or subfertile male including treatment with gonadotropins (HCg, FSH), selective estrogen receptor modulators (i.e., clomiphene citrate), aromatase inhibitors (i.e., arimidex, letrozole), and prolactin altering agents (i.e., dostinex, bromocriptine). The use of the agents, both alone and in combination, is detailed in the current chapter.